Relationship Between White Opaque Substance Observed by Magnifying NBI Endoscopy Under Intragastric Neutralization and Gastric Cancer Risk: A Pilot Study

Relationship Between White Opaque Substance Observed by Magnifying NBI Endoscopy Under Intragastric Neutralization and Gastric Cancer Risk: A Pilot Study - PPI-WOS-GIM study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060761

Enrollment

200

Registered

2026-02-26

Start date

2025-07-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic gastritis, gastric intestinal metaplasia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria for the gastric cancer group 1. Patients with a histologically confirmed diagnosis of gastric cancer based on biopsy. 2. Patients who require upper gastrointestinal endoscopy at Fukuoka University Chikushi Hospital for the treatment or further evaluation of gastric cancer. 3. Patients aged 20 years or older. 4. Patients who have been receiving any proton pump inhibitor for at least 1 week. 5. Patients who have provided written informed consent for study participation. Inclusion criteria for the non-gastric cancer group 1. Patients who require upper gastrointestinal endoscopy at Fukuoka University Chikushi Hospital for any reason. 2. Patients with no prior history of gastric cancer. 3. Patients aged 20 years or older. 4. Patients who have been receiving any proton pump inhibitor for at least 1 week. 5. Patients who have provided written informed consent for study participation.

Exclusion criteria

Exclusion criteria: 1. Patients in whom adequate observation of the gastric mucosa is difficult. 2. Patients with a history of gastrectomy. 3. Patients at high risk of bleeding from biopsy due to underlying conditions such as hepatic dysfunction, renal dysfunction, or coagulation disorders. 4. Patients in whom biopsy cannot be performed due to the use of anticoagulant or antiplatelet agents.

Design outcomes

Primary

Measure	Time frame
Comparison of WOS scores between patients with and without gastric cancer.	—

Secondary

Measure	Time frame
1. Association between the development of gastric cancer and each risk factor (WOS score, EGGIM score, degree of OLGIM classification, degree of gastric mucosal atrophy, alcohol consumption, smoking, family history of gastric cancer, and H. pylori infection status). 2. Frequency of synchronous and metachronous multiple gastric cancers according to WOS score. 3. Comparison of LBC scores between patients with and without gastric cancer.	—

Measure

Time frame

1. Association between the development of gastric cancer and each risk factor (WOS score, EGGIM score, degree of OLGIM classification, degree of gastric mucosal atrophy, alcohol consumption, smoking, family history of gastric cancer, and H. pylori infection status). 2. Frequency of synchronous and metachronous multiple gastric cancers according to WOS score. 3. Comparison of LBC scores between patients with and without gastric cancer.

—

Countries

Japan

Contacts

Public ContactTakao Kanemitsu

Fukuoka University Chikushi Hospital Department of Gastroenterology

t.kanemitsu93@gmail.com0570-02-7777

Outcome results